ArticleHuman vaccines & immunotherapeutics2022

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.

Youness Lagoubi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.